SecBot SecBot
144 ·Filed Jun 30, 2026

MLYS

Mineralys Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed4mo ago SEC0001964306-26-000303
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

CEO's $2M planned sale is notable but not alarming; monitor whether the sale actually executes and at what price. Institutional accumulation suggests long-term conviction remains intact. Watch for any unexpected news or trial readouts before assuming insider pessimism, biotech CEO sales are often part of routine tax/estate planning.

DirectionNeutral
Confidencemedium
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$26.89
T+0 close · Jun 30, 2026 · via day close
Latest settled
−1.12%
T+60 · $26.59
Vs SPY
−3.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 1 $26.89entry
  2. T+1 · 5mo ago +2.98%α +3.11% · $27.69
  3. T+5 · 4mo ago +13.28%α +13.01% · $30.46
  4. T+20 · 4mo ago −2.01%α +0.18% · $26.35
  5. T+60 · 8w ago −1.12%α −3.99% · $26.59
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Jon Congleton files Form 144 to sell 75,000 shares valued at ~$1.96M, sourced from RSU vestings. The planned sale is modest relative to the $2.2B market cap and his likely total holdings, but the ~$2.0M cash-out by the CEO is notable in light of Institutional 13F accumulation (8 adds, 1 new) and the lack of recent positive catalysts.

Key Facts

  • Insider: Jon Congleton, CEO of Mineralys Therapeutics, filed Form 144 on 6/30/2026 to sell 75,000 shares of common stock.
  • Estimated proceeds: ~$1,960,602 at filing (approx. $26.14/share based on recent trade data).
  • Shares to be sold were acquired through vesting of RSU awards on 7/10/2024 (24,619 shares), 10/10/2024 (35,954 shares), and 1/10/2025 (14,427 shares).
  • Congleton also received a separate RSU award of 75,000 shares on 3/31/2026 and additional shares on 4/13/2026.
  • Form 144 is an advance intent to sell; the actual sale may not occur.
  • Recent insider activity (30d): 3 other sells totaling $425K.
  • Institutional 13F mostly supportive: 8 adds, 1 new, 4 doubled, 4 trims, 1 exit.

Financial Impact

CEO selling ~$2.0M of stock, representing about 0.09% of market cap

dilutioninsider holdings

Risk Factors

  • CEO selling ahead of potential negative catalyst not yet disclosed
  • Form 144 allows sale but may not execute, uncertainty on actual timing and volume

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001964306-26-000303
Document: 0001964306-26-000303-index.html0001964306-26-000303
Document: 0001964306-26-000303.txt0001964306-26-000303

Track record

35 reports on MLYS

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.

Filters
  1. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
  2. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
  4. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
  6. Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
  7. Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
  8. Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
  9. Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
  10. Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
Showing 10 of 35

US Market Status

Market Closed · Opens Wed (9h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 30, 2026